Response rate as a regulatory end point in single-arm studies of advanced solid tumors

JAMA Oncology

Volumn 2, Issue 6, 2016, Pages 772-779

  Oxnard, Geoffrey R ^a   Wilcox, Katharine H ^a   Gonen, Mithat ^b   Polotsky, Mikhael ^c   Hirsch, Bradford R ^d   Schwartz, Lawrence H ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Surgeos and New York Presbyterian Hospital ^*  (United States)

^d DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOASSAY; CLINICAL TRIAL (TOPIC); HUMAN; META ANALYSIS; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS;

EID: 85010654002     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.6315     Document Type: Article

References (28)

1. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
3. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279.
4. Sherman RE, Li J, Shapley S, Robb M,Woodcock J. Expediting drug development-the FDA's new "breakthrough therapy" designation. N Engl J Med. 2013;369(20):1877-1880.
5. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32 (1):40-51.
6. Lipson D, CapellettiM, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384.
7. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21):6821-6828.
8. KwokM, Foster T, SteinbergM. Expedited programs for serious conditions: an update on breakthrough therapy designation. Clin Ther. 2015; 37(9):2104-2120.
9. Cavallo J. A look ahead: how the FDA is adapting in the era of precision medicine. ASCO Post. 2013;4(17). http://www.ascopost.com/issues /november-1,-2013/a-look-ahead-how-the-fda-is -adapting-in-the-era-of-precision-medicine.aspx. Accessed February 3, 2016.
10. Kesselheim AS,Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ. 2015;351:h4633.
11. Lamont EB, Hayreh D, Pickett KE, et al. Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst. 2003;95(18):1370-1375.
12. Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104(20):1534-1541.
13. Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014;106(7):dju163.
14. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9): 1008-1014.
15. Hirsch BR, Califf RM, Cheng SK, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med. 2013;173(11):972-979.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92(3):205-216.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
18. Bowman AW, Azzalini A. Computational aspects of nonparametric smoothing with illustrations from the sm library. Comput Stat Data Anal. 2003;42(4):545-560.
19. Kruskal WH. Ordinal measures of association. J A Stat Assoc. 1958;53(284):814-861.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3): 837-845.
21. Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. Arch Pathol Lab Med. 2012;136(10):1205-1209.
22. Janne PA, Yang JC-H, Kim D-W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689-1699.
23. Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061.
24. Janne PA, Ou S-HI, Kim D-W, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15(13):1433-1441.
25. Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther. 2015;9:2883-2886.
26. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
27. Molecular Analysis for Therapy Choice (NCI MATCH). 2015. http://dctd.cancer.gov/MajorInitiatives/NCI-MATCH.pdf. Accessed November 10, 2015.
28. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963-1971.